CSL Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals

A real-world evidence (rwe) study recently published in open forum infectious diseases (ofid) examined three consecutive u.s. flu seasons in the united states. the study suggests that cell-based quadrivalent influenza vaccine (qivc) may have the potential to be more effective than egg-based vaccines (qive) in preventing test-confirmed influenza.

First non-immunosuppressive therapy for the treatment of iga nephropathy (igan) approved in europe conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-iii protect trial st. gallen, switzerland and san diego, april 24, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that the european commission has granted conditional marketing authorization (cma) for filspari (sparsentan) for the treatment of adults with primary igan with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

St. gallen, switzerland , march 19, 2024 /prnewswire/ -- csl vifor today announced that health canada has authorized ferinject (ferric carboxymaltose) for the intravenous (iv) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and new york heart association (nyha) class ii/iii* 1 to improve exercise capacity.2 ferinject has now received marketing authorization in 87 countries worldwide. research shows that rates of iron deficiency are even higher than previously reported in canada, with the condition particularly prevalent in women of reproductive age3 and children4.

Summit, n.j. , march 6, 2024 /prnewswire/ -- csl seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 u.s. season, based on the trivalent strains recommended this week by the u.s. food and drug administration's (fda) vaccines and related biological products advisory committee (vrbpac).

Committee for medicinal products for human use (chmp) recommends approval of the conditional marketing authorization (cma) for sparsentan for the treatment of iga nephropathy (igan) in europe positive chmp opinion is based on pivotal phase-iii protect study results european commission decision is expected in q2 2024 st. gallen, switzerland , feb. 23, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that the european medicines agency's (ema) chmp has recommended approval of sparsentan for the treatment of adults with primary igan with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript

CSL Limited (OTCQX:CSLLY) Q4 2023 Earnings Conference Call August 14, 2023 9:00 PM ET Company Participants Mark Dehring - Head of Investor Relations Paul McKenzie - Chief Executive Officer Joy Linton - Chief Financial Officer Bill Campbell - Executive Vice President and Chief Commercial Officer Conference Call Participants Lyanne Harrison - Bank of America Merrill Lynch Andrew Goodsall - MST Marquee Sean Laaman - Morgan Stanley Steven Wheen - Jarden Australia Pty Limited Saul Hadassin - Barrenjoey Markets Pty Limited David Low - JPMorgan Chase & Co. Laura Sutcliffe - UBS Craig Wong-Pan - Royal Bank of Canada Chris Cooper - Goldman Sachs Group, Inc. Mathieu Chevrier - Citigroup Inc. David Bailey - Macquarie Research Mark Dehring Ladies and gentlemen, good morning and welcome to CSL's Full-Year Results Call for Fiscal 2023...

Australia's CSL reported an annual profit on Tuesday that rose 8% as higher plasma collections helped the biotech company counter the impact of currency fluctuations and higher costs.

AGO, BATL and CSLLY have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2023.

The top and bottom-line growth make these Zacks Medical stocks very attractive.

CSL Limited (OTCPK:CSLLY) Q2 2023 Earnings Conference Call February 13, 2023 7:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Paul McKenzie - Chief Operating Officer Conference Call Participants David Stanton - Jefferies Andrew Goodsall - MST Marquee David Low - JPMorgan Lyanne Harrison - Bank of America Chris Cooper - Goldman Sachs Steve Wheen - Jarden Sean Laaman - Morgan Stanley Saul Hadassin - Barrenjoey Gretel Janu - Credit Suisse Craig Wong-Pan - RBC David Bailey - Macquarie Mark Dehring Ladies and gentlemen, good morning and welcome to CSLs First Half Results call for Fiscal 2023. It's Mark Dehring speaking and joining me online is Paul Perreault, CSL's, Chief Executive Officer; Paul McKenzie, CSL's, incoming Chief Executive Officer and Joy Linton, CSL's, Chief Financial Officer.

CSL Limited Sponsored ADR (CSLLY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

CSL Limited's recent R&D investor briefing suggests that the company has been able to build a strong R&D pipeline without overspending. Separately, CSL Limited expects the top line of its recently acquired pharmaceuticals company to generate a reasonably good revenue CAGR above +10% for the midterm.